Trianex (Triamcinolone Acetonide Ointment) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - September 25, 2019 Category: Drugs & Pharmacology Source Type: news
Clearside Biomedical Provides New Drug Application Update for Xipere (triamcinolone acetonide suprachoroidal injectable suspension)
ALPHARETTA, Ga., Aug. 22, 2019 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - August 22, 2019 Category: Drugs & Pharmacology Source Type: news
Protopic Ointment vs. Triamcinolone
Title: Protopic Ointment vs. TriamcinoloneCategory: MedicationsCreated: 8/13/2019 12:00:00 AMLast Editorial Review: 8/13/2019 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - August 13, 2019 Category: Drugs & Pharmacology Source Type: news
triamcinolone acetonide nasal inhaler (Nasacort)
Title: triamcinolone acetonide nasal inhaler (Nasacort)Category: MedicationsCreated: 4/6/1999 12:00:00 AMLast Editorial Review: 3/11/2019 12:00:00 AM (Source: MedicineNet Allergies General)
Source: MedicineNet Allergies General - March 11, 2019 Category: Allergy & Immunology Source Type: news
Oralone (Triamcinolone Acetonide Dental Paste) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - January 30, 2019 Category: Drugs & Pharmacology Source Type: news
What Complications Can Gastrostomy Tubes Have?
Discussion
Gastrostomy tubes (GT or GTubes) have been used to support patients for about a century. They are placed between the abdominal skin and the stomach either percutaneously or surgically. The tubes can be a standard long tube with either a bumper or inflatable balloon internally and externally they have a retention piece to hold the GT in place. A button or low profile tube are similar but extend just beyond the skin.
Reasons for GT placement include:
Nutritional support
Hydration maintenance
Medication management
Aspiration avoidance
Gastric stasis decompression
Obstruction bypass
Quality of life improvement for...
Source: PediatricEducation.org - January 21, 2019 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news
Clearside Biomedical reports analyses from pivotal trial of eye drug
Clearside Biomedical (NSDQ:CLSD) touted new analyses of data from the company’s Phase III pivotal trial of suprachoroidal CLS-TA in people with uveitic macular edema.
The company’s investigational treatment is a suspension of triamcinolone acetonide formulated to be delivered to the back of the eye via the suprachoroidal space.
Get the full story at our sister site, Drug Delivery Business News.
The post Clearside Biomedical reports analyses from pivotal trial of eye drug appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - October 29, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Pharmaceuticals Wall Street Beat Clearside Biomedical Source Type: news
Flexion reports data from Phase II bilateral osteoarthritis trial
Flexion Therapeutics (NSDQ:FLXN) touted data today from a Phase II trial assessing the bilateral dosing of its extended-release triamcinolone acetonide injection in people with bilateral osteoarthritis.
The study found that bilateral injections of Flexion’s Zilretta therapy resulted in lower plasma concentrations of triamcinolone acetonide compared to immediate-release triamcinolone acetonide in crystalline suspension (TAcs). The company also noted that concurrent administration of Zilretta was well tolerated among the study’s participants.
Get the full story at our sister site, Drug Delivery Business News.
The post F...
Source: Mass Device - October 22, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Orthopedics Pharmaceuticals Wall Street Beat Flexion Therapeutics Source Type: news
Ellzia Pak (Triamcinolone Acetonide Ointment ) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - October 17, 2018 Category: Drugs & Pharmacology Source Type: news
Golden Future Expos Inc. Announces Flexion Therapeutics, Inc. as the...
Visit booth #203-204 to learn more about ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), Flexion’s approved non-opioid treatment for osteoarthritis knee pain(PRWeb October 15, 2018)Read the full story at https://www.prweb.com/releases/golden_future_expos_inc_announces_flexion_therapeutics_inc_as_the_presenting_sponsor_at_the_upcoming_orange_county_50_senior_expo/prweb15833842.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - October 15, 2018 Category: Pharmaceuticals Source Type: news
Anika shares plummet after Phase III trial misses endpoint
Shares in Anika Therapeutics (NSDQ:ANIK) fell more than -30% this week after the company reported that its osteoarthritis drug, Cingal, failed in a Phase III trial.
The therapy, designed to treat osteoarthritis of the knee, is a combination of cross-linked hyaluronic acid and triamcinolone hexacetonide. The trial’s primary endpoint compared the pain reduction experienced by patients treated with Cingal compared to those treated with just TH at 26 weeks.
Get the full story at our sister site, Drug Delivery Business News.
The post Anika shares plummet after Phase III trial misses endpoint appeared first on MassDevice....
Source: Mass Device - June 21, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Pain Management Pharmaceuticals Wall Street Beat Anika Therapeutics Inc. Source Type: news
Flexion touts interim data from Ph3 trial of osteoarthritis injection
Flexion Therapeutics (NSDQ:FLXN) this week touted updated, interim results from an ongoing Phase IIIb study evaluating the safety and tolerability of repeat administration of its osteoarthritis injection, Zilretta.
The company’s injectable suspension is an extended-release formulation of triamcinolone acetonide designed for patients with osteoarthritis of the knee. Top-line results from Flexion’s trial showed that 95% of the study’s 205 patients experienced clinical benefit 12 weeks after their first injection of Zilretta. 179 patients received a second dose of the drug between weeks 12 and 24, the company said.
Get...
Source: Mass Device - April 27, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Orthopedics Pain Management Pharmaceuticals Wall Street Beat Flexion Therapeutics Source Type: news
Kenalog-40 Injection (Triamcinolone Acetonide Injectable Suspension) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - April 25, 2018 Category: Drugs & Pharmacology Source Type: news
Clearside Biomedical enrolls first patient in Ph3 macular edema trial
Clearside Biomedical (NSDQ:CLSD) has enrolled the first patient in a Phase III trial evaluating its eye drug combined with an intravitreally-administered anti-VEGF agent as a treatment for macular edema associated with retinal vein occlusion.
The company’s drug, CLS-TA, is a proprietary suspension of triamcinolone acetonide designed to be administered in the space located between the choroid and the sclera.
Get the full story at our sister site, Drug Delivery Business News.
The post Clearside Biomedical enrolls first patient in Ph3 macular edema trial appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - March 6, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Optical/Ophthalmic Pharmaceuticals Wall Street Beat Clearside Biomedical Source Type: news
Clearside Biomedical shares soar after eye drug succeeds in Ph3 trial
Clearside Biomedical (NSDQ:CLSD) shares soared more than 50% in pre-market activity today after the company reported that its suprachoroidal eye drug succeeded in a pivotal Phase III trial of patients with macular edema associated with non-infectious uveitis.
The company’s drug, CLS-TA, is a proprietary suspension of a corticosteroid, triamcinolone acetonide, designed to be administered to the back of the eye via the suprachoroidal space.
Get the full story at our sister site, Drug Delivery Business News.
The post Clearside Biomedical shares soar after eye drug succeeds in Ph3 trial appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - March 5, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Optical/Ophthalmic Pharmaceuticals Wall Street Beat Clearside Biomedical Source Type: news
